Study subjects
Patients with a documented clinical history of fish allergy (n=263) were
recruited from six countries (Austria, China, Denmark, Luxembourg,
Norway and Spain). Their demographic and clinical characteristics are
summarized in Table I and detailed in Table SI .
Sensitization to fish was confirmed by ImmunoCAP (ThermoFisher
Scientific), skin prick tests (SPT) to fish extracts and/or
prick-to-prick test (PPT) to fresh fish for 255 patients. Total IgE
measured by ALEX2 (MacroArray Disgnostics) and
ImmunoCAP demonstrated a significant positive correlation (Spearman’s
Rho=0.88) (Figure S1 ). Fish allergy symptoms’ severities were
scored from 1 to 4 (Table 1) . Anaphylaxis scoring was performed
according to Ring et al.14 Distribution of age groups
and sex among the participants from each country is shown inFigure S2 .
Informed written consent was obtained from all participants or their
legal representatives and the study was approved by the Ethics
Committees of the participating institutions: Austria- Ethics Committee
of the city of Vienna (EK-12-126-0712); China- Joint CUHK-NTEC CREC
(2017.542); Denmark- (S-20210170); Luxembourg- CNER approval
(201307/04); Norway- REK (2013/ 757); Spain- Hospital Clínic de
Barcelona (HCB/2021/1129) and Hospital Sant Joan de Déu, Esplugues de
Llobregat (PIC-97-20).